How the FDA Classifies Research Peptides in 2026

By NorthPeptide Research Team  |  May 10, 2026

The FDA’s Regulatory Vocabulary for Peptides

Before diving into categories, it helps to understand the overlapping frameworks the FDA applies to peptide-like substances. Three frameworks are most relevant to the research peptide space:

1. New Drug Application (NDA) / Biologics License Application (BLA): For peptides approved as drugs (e.g., semaglutide as Ozempic/Wegovy, tesamorelin as Egrifta). These are fully regulated pharmaceutical products.
2. Section 503A/503B Compounding: Governs pharmacy compounding of unapproved substances. This is where the Category 1/2/3 framework lives — it determines which substances can be compounded for patient-specific prescriptions.
3. Research Chemical / Non-Pharmaceutical: Covers substances sold explicitly for laboratory research, not for human or veterinary use. This is the framework under which most “research peptide” vendors operate.

These frameworks are not mutually exclusive — a peptide can be an approved drug under NDA, also compoundable under 503A, and also available as a research chemical. The legal significance of each route differs substantially.

The 503A/503B Category System: What It Actually Means

The Bulk Drug Substances list

Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), the FDA maintains a list of bulk drug substances that can be used in compounding. Substances not on this list cannot be lawfully compounded by pharmacies for patient use.

The FDA divides substances being evaluated for this list into three categories:

Category 1 — Nominated, Under Review

Category 1 contains bulk drug substances that have been nominated for inclusion on the 503A or 503B lists and are currently under active review. During the review period, substances in Category 1 may be compounded under certain conditions while the FDA evaluates the clinical need and safety profile.

Examples that were or are in Category 1 include: Sermorelin, CJC-1295, Ipamorelin, GHRP-2, and various other growth hormone secretagogues.

Category 2 — Nominated but Not Recommended for Compounding

Category 2 is the critical category for understanding the 2024–2025 reclassification wave. Substances in Category 2 have been reviewed and the FDA has determined they should NOT be included on the 503A/503B bulk drug substance lists — meaning they cannot be compounded for human use by licensed pharmacies.

The FDA’s reasoning for Category 2 placement varies: some substances have an approved drug equivalent (making compounding unnecessary), others have raised safety concerns, and others lack sufficient clinical data to support compounding inclusion.

Key substances reclassified to Category 2 (and therefore no longer compoundable) include:

• BPC-157
• TB-500 (Thymosin Beta-4)
• Selank
• Semax
• Epithalon
• AOD-9604
• GHK-Cu (copper peptide)

This reclassification does not make these substances illegal to possess or to sell for research purposes. It specifically removes them from the list of substances that licensed pharmacies can compound for patient prescriptions.

Category 3 — Additional Information Requested

Category 3 substances have been reviewed but the FDA has requested additional information from nominators before making a final determination. These substances occupy a holding pattern — neither approved for nor excluded from compounding pending further data submission.

The 2024–2025 Reclassification Wave

In 2024 and into 2025, the FDA accelerated its review and final categorisation of dozens of peptides that had existed in a grey zone — nominally under review but widely compounded. The consequence was a significant contraction of what compounding pharmacies could legally offer.

What drove the acceleration

Several factors converged: increased congressional and regulatory attention on compounding pharmacy practices following high-profile adverse events; the GLP-1 weight loss boom drawing scrutiny to the compounding of semaglutide and tirzepatide; and longstanding pressure from pharmaceutical manufacturers whose approved products were being undercut by compounded alternatives.

The semaglutide compounding saga

Semaglutide occupied a special position: it was designated a drug in shortage, which under Section 503B permits outsourcing facilities to compound it during the shortage period. As FDA shortage designations were lifted in late 2024 and early 2025, compounders were given transition periods to wind down, generating significant legal conflict and enforcement action in that space.

Impact on the broader peptide landscape

The Category 2 placements for BPC-157, TB-500, and related compounds effectively removed them from the legitimate compounding pharmacy channel. Researchers who previously obtained these compounds via prescription from compounding pharmacies lost that avenue. The research chemical market — which operates under a different legal basis entirely — was not directly affected by these categorisation decisions.

The SAFE Act and Its Implications

The Subcutaneous Administration for Everyone (SAFE) Act, introduced in Congress in 2024 and still being debated in 2026, seeks to create a formal regulatory pathway for peptide compounds used in clinical research settings. Proponents argue that the current regulatory structure leaves a gap — substances that have meaningful research interest but no FDA-approval pathway find themselves in an uncertain legal space.

Key provisions discussed in SAFE Act iterations include:

• A new classification tier for substances with published safety data but not pursuing full NDA approval
• A registry system for clinical researchers using these substances
• Defined quality standards (similar to USP standards) for research-grade production

As of 2026, the SAFE Act has not passed into law. However, its discussion has influenced how FDA enforcement is being prioritised — with attention focused more heavily on manufacturers and less on end-user researchers in academic and licensed clinical settings.

What “For Research Purposes Only” Actually Means Legally

This phrase is the foundation on which the research chemical market operates, and it is frequently misunderstood in both directions.

What it means

A substance sold “for research purposes only, not for human use” is being positioned outside the pharmaceutical distribution framework. The FDA’s jurisdiction over drug distribution requires a product to be intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or animals. If a product is genuinely intended for laboratory research — in vitro studies, analytical chemistry, pharmacology research — it does not, under that intended use, constitute a drug under the FD&C Act.

This is why research chemical vendors can legally sell substances without FDA approval: the FDA’s drug approval framework applies to drugs intended for human/animal therapeutic use, not to research chemicals intended for laboratory study.

What it does not mean

The “research only” designation does not:

• Make a substance legal to administer to humans in a clinical or personal context
• Shield a vendor from prosecution if their marketing clearly implies human use (the FDA evaluates “intended use” based on all available evidence, including marketing language, customer communications, and accompanying materials)
• Override any state-level regulations that may apply independently of federal FDA jurisdiction

The intended use doctrine

The FDA applies the “intended use” doctrine strictly. If a vendor markets a peptide with before/after weight loss photos, dosing guides for humans, or testimonials about personal use results, the FDA can argue that the actual intended use is human therapeutic — regardless of a “research only” disclaimer on the label. This is where enforcement actions most commonly arise.

Compounding Pharmacy Regulations: Current State

For substances that remain on the 503A/503B Category 1 list — still under review and compoundable during review — licensed compounding pharmacies can prepare these compounds with a valid patient-specific prescription from a licensed practitioner.

The current Category 1 compoundable list (as of 2026) still includes some GH secretagogues and related compounds that survived the reclassification wave, though this list continues to be updated as reviews complete.

Outsourcing facilities (503B) operate under stricter cGMP manufacturing requirements and can compound without patient-specific prescriptions — but only substances the FDA permits and only for defined healthcare facility use.

State-Level Variations

Federal FDA jurisdiction is not the entire picture. State boards of pharmacy regulate compounding within their borders and can impose requirements that exceed federal minimums. Some states have adopted stricter definitions of what qualifies as a legitimate research use; others have been more permissive.

International jurisdiction adds further complexity. Peptides that are research chemicals in the United States may have different legal status in the European Union (under EMEA frameworks), in Norway (under the Norwegian Medicines Agency, Statens legemiddelverk), or in other jurisdictions. Cross-border shipment of research chemicals is governed by both the exporting and importing country’s regulations, as well as customs classifications that are still evolving for this category of substance.

Summary: The Current Legal Landscape

References

1. U.S. Food and Drug Administration. (2024). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. FDA.gov.
2. U.S. Food and Drug Administration. (2024). Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act. FDA.gov.
3. Allen LV. (2012). The Art, Science, and Technology of Pharmaceutical Compounding. 4th ed. American Pharmacists Association.
4. U.S. Food and Drug Administration. (2023). Guidance for Industry: Compounding Under the Federal Food, Drug, and Cosmetic Act Sections 503A and 503B.
5. Gudeman J, et al. (2013). Potential risks of pharmacy compounding. Drugs R D. 13(1):1–8. PMID: 23322002.
6. Congressional Research Service. (2024). FDA Regulation of Drug Compounding: A Legal Overview.